Mr Walter H Wainright
Founder and Chief Counselor for Haelan Research Foundation, a United States Government approved 501(c) (3) Public Foundation.

Mr. Wainright, an honors graduate of Tulane University, is an internationally known lecturer with 17 years experience in researching the prevention and treatment of cancer and other chronic diseases with soy phytochemicals. Mr. Wainright’s research has received recognition by the National Cancer Institute (USA) and is currently being researched at the M.D. Anderson Cancer Center in the United States and several leading cancer centers in Europe. Mr. Wainright is collaborating with the Institute for molecular oncology in Recklinghausen, Germany on reversing DNA damage in cancer cells with soy phytochemicals. He has designed and completed clinical trials in Asia, Europe and the United States showing the human health benefits of dietary soy phytochemicals.  His research and experience with humans documents the benefits of soy therapy for estrogen receptor positive breast, prostate and other cancers.  Mr. Wainright’s research also addresses how the soy phytochemicals protect cancer patients from chemotherapy induced cell mutations, related toxicity, infections and anemia as well as enhanced cancer cell killing effectiveness 8-10 times greater than chemotherapy treatments by themselves.

2007 - Are Soy Phytoestrogens Ideal for Preventing Chronic Diseases and Treating Cancer?

There are more than 4,400 Phytoestrogens in the plant kingdom.  None have been researched more than the soy-phytoestrogens for their beneficial health effects. Epidemiological studies clearly show lower cancer (breast, prostate, ovarian) and other chronic diseases in Asian countries with high intake of Isoflavones. Conclusions from soy studies have been controversial because uniformity has been lacking in what constitutes a “soy” study.  Whole soy versus soy protein or isolates from soy; fermented soy versus unfermented soy; concentrations and types of soy Isoflavones and/or their metabolites are different in studies.  All soy products are not equal and results vary depending on the soy composition and its processing. 

Eighty percent of advanced cancer patients die from protein calorie malnutrition. This condition is enhanced by the toxic side effects of chemotherapy and radiation treatments which promote mal absorption, fatigue, nausea, vomiting, depression and stress that further decreases immune function and the patient’s will to live.  In the field of cancer, fermented soy proteins and photochemicals are establishing a strong position for their incorporation in the cancer patient’s diet. The National Cancer Institute has documented, as part of its “Best Case Series” program, sole therapy treatment with fermented soy improves both the quality of life and lifespan of terminal cancer patients. Some terminal cancer patients became cancer free and remained cancer free for more than five years.   

A $20 million NCI study in fruits and vegetables discovered five effective classes of anti-cancer compounds. All are in soybeans!  These were identified as isoflavones, protease-inhibitors, phytosterols, saponine and phytic-acid compounds. The soybean contains anti-viral, anti-allergy, anti-inflammatory, vasodilator, and anti-cancer compounds.  There are more than 9,000 studies on soy and its beneficial compounds performed since the NCI published there paper in April, 1991. Many of these studies show that unfermented soy products have drawbacks contrary to fermented soy that indicated to be more beneficial. The mechanisms of action include DNA repair, anti-angiogenesis, restoration of apoptosis, immune stimulation, detoxification, improved estrogen metabolism, enhanced organ function, reduction of cell division times (mitosis), suppression of cancer  promoting genes,  and prevention of cancer cell mutations induced by chemotherapy.

Conclusion:  Fermented soy products are known to contain high concentrations of Isoflavones, protease inhibitors, saponine, phytosterols, and phytic acid compounds that exhibit anticancer activity in preclinical models.  Research supports the prospective evaluation of fermented soy products as an alternative therapy in patients with chemotherapy refractory ovarian cancer and other cancers that are not responsive to chemotherapy.  The use of these products to enhance chemotherapy, reduce toxic effects of chemotherapy and prevent mutations induced by chemotherapy offers new hope for many patients.  In addition, these products can help the physician manage disease while it is treated with conventional therapies resulting in improved treatment compliance and patient outcomes.  The greater role of soy phytoestrogens and the other soy compounds may be found in the field of anti-aging and preventive medicine because of their ability to repair DNA resulting in the prevention of diseases or improvement in disease conditions caused by existing DNA damage.